Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22269278 | 0.93 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1CNR2 | |
| SCHEMBL7648702 | 0.88 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17815829 | 0.84 | SLC6A4 (0.33) | — | |
| SCHEMBL4437885 | 0.84 | — | — | |
| Oxirane SCHEMBL5318158 | 0.82 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| Oxirane SCHEMBL7112127 | 0.82 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| Oxirane SCHEMBL7112144 | 0.82 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17607279 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17731291 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1868334 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240117269-A1 | NOVEL AROMATIC MONOTHIOKETALS AS FRAGRANCE COMPOUNDS | SYMRISE AG (DE) | 2024-04-11 | — | — | US | disclosed |
| US-20020040047-A1 | Novel Use | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | US | disclosed |
| US-20020040047-A1 | Novel Use | ASTRAZENECA AB (SE) | 2002-04-04 | — | — | US | disclosed |
| CN-1052002-C | Ether derivatives of tetrahydropyran and tetrahydrofuran, process for their preparation and pharmaceutical compositions containing them | ZENECA LTD (GB) | 2000-05-03 | — | — | CN | disclosed |
| EP-0623614-B1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1998-02-25 | — | — | EP | disclosed |
| CN-1121715-A | 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| CN-1121715-A | 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040047-A1 | Novel Use | FPR3, NOX4, LTC4S | OPRM1 485/4885OPRD1 103/4885OPRK1 165/4885 |
| US-20240117269-A1 | NOVEL AROMATIC MONOTHIOKETALS AS FRAGRANCE COMPOUNDS | TRPA1, TRPM5, TRPC5 | OPRM1 306/4885OPRD1 391/4885OPRK1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.